Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacological differences between R(-)- and S(+)-ibuprofen.

G Geisslinger1, K P Stock, G L Bach

  • 1Department of Pharmacology, University of Erlangen, FRG.

Agents and Actions
|June 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The alternative NF-κB RelB subunit is a novel critical sensor of lipid metabolism to promote tumor development.

Cell death & disease·2026
Same author

Endocannabinoid analysis in GlucoEXACT plasma: Method validation and sample handling recommendations.

Talanta·2024
Same author

Metabolomic and lipidomic fingerprints in inflammatory skin diseases - Systemic illumination of atopic dermatitis, hidradenitis suppurativa and plaque psoriasis.

Clinical immunology (Orlando, Fla.)·2024
Same author

Pre-analytical sample handling standardization for reliable measurement of metabolites and lipids in LC-MS-based clinical research.

Journal of mass spectrometry and advances in the clinical lab·2023
Same author

Post-mortem changes of prostanoid concentrations in tissues of mice: Impact of fast cervical dislocation and dissection delay.

Prostaglandins & other lipid mediators·2022
Same author

Pre-analytical challenges for the quantification of endocannabinoids in human serum.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2022
Same journal

Classification and biological distribution of histamine receptor sub-types. 1975.

Agents and actions·1994
Same journal

Metiamide--an orally active histamine H2-receptor antagonist. 1973.

Agents and actions·1994
Same journal

A brief survey of the history of inflammation. 1978.

Agents and actions·1994
Same journal

The discovery of librium. 1972.

Agents and actions·1994
Same journal

Notes and documents concerning the discovery of LSD. 1970.

Agents and actions·1994
Same journal

Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41,468), a selective 5-HT2-receptor antagonist. 1982.

Agents and actions·1994
See all related articles

Administering the S(+)-enantiomer of ibuprofen (IBU) offers advantages over the racemic mixture. This active isomer provides greater therapeutic benefits with potentially reduced metabolic load for patients.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Chirality

Background:

  • Ibuprofen (IBU) is a non-steroidal anti-inflammatory drug (NSAID) with optical isomerism; only the S(+)-enantiomer inhibits the PG synthetase system.
  • Current clinical use involves the racemic mixture, despite in vitro evidence favoring the S(+)-enantiomer.
  • The conversion of the inactive R(-)-IBU isomer in vivo is believed to negate advantages of administering the pure active isomer.

Purpose of the Study:

  • To compare the pharmacokinetic and clinical efficacy of S(+)-ibuprofen, R(-)-ibuprofen, and racemic ibuprofen.
  • To investigate the in vivo conversion and bioavailability of ibuprofen enantiomers.
  • To assess the therapeutic potential of administering the S(+)-enantiomer of ibuprofen for rheumatoid arthritis.

Main Methods:

Related Experiment Videos

  • A triple cross-over study involving 8 participants comparing 300 mg S(+)-IBU, 300 mg R(-)-IBU, and 600 mg racemic IBU.
  • Pharmacokinetic analysis including area under the curve (AUC) and peak plasma levels of S(+)-IBU.
  • A subsequent study involving 4 rheumatoid arthritis patients treated with 500 mg S(+)-IBU twice or thrice daily for two weeks.

    • Main Results:

    • R(-)-IBU conversion after racemic administration yielded only one-third the AUC of S(+)-IBU from S(+)-application.
    • Highest S(+)-peak plasma levels were achieved after S(+)-IBU administration, with lower levels after racemic IBU.
    • Rheumatoid arthritis patients showed significant clinical recovery within one week of S(+)-IBU treatment (Ritchie index, pain, and motion scores improved significantly).

    Conclusions:

    • The S(+)-enantiomer of ibuprofen demonstrates superior pharmacokinetic and clinical outcomes compared to racemic ibuprofen.
    • Administration of the S(+)-enantiomer allows for a potential reduction in dosage and metabolic load.
    • These findings support the use of the S(+)-enantiomer as a potentially more effective and efficient therapeutic option.